VivoSeq
Dermatology

Androgenetic Alopecia

42

Pipeline Programs↗

20

Active Trials↗

26

Companies Involved↗

Androgenetic Alopecia is a moderately active landscape with 42 programs across 26 companies. The most active players are Follicle Pharma Ltd, Technoderma Medicines Inc., Biosplice Therapeutics, Inc.. 5 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

34/100

Mech. Concentration

22/100

Completion Rate

88/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Follicle Pharma Ltd

2 programs

Phase 1T

Technoderma Medicines Inc.

2 programs

Phase 2B

Biosplice Therapeutics, Inc.

1 program

Phase 2I

Intrepid Therapeutics, Inc.

1 program

Phase 2O

Olix Pharmaceuticals, Inc.

1 program

Phase 2R

Restore Biologics Holdings, Inc. dba Xtressé

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

50 of 54 classified programs — the dominant modality here.

7%ALL OTHERSCell therapy47%

Small molecule leads; the ring shows all 54 classified programs, each share of the total. Modality classified for 100% of 63 pipeline programs.

Analysis

Trial Status

78

clinical trials

Completed37 · 47%
Unknown status16 · 21%
Not yet recruiting9 · 12%
Recruiting9 · 12%
Withdrawn4 · 5%
Terminated1 · 1%
Other2 · 3%

Clinical Trials

Trial Activity

78 trials

Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
Recruiting·SShanghai Zhongshan Hospital·Phase 1·NCT07012486·30 enrolled
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
Recruiting·ZZhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.·Phase 3·NCT07080931·294 enrolled
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Recruiting·VVeradermics, Inc.·Phase 3·NCT07146022·552 enrolled
Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia
Recruiting·EEMS·Phase 3·NCT04594018·190 enrolled
Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia
Recruiting·FFollicle Pharma Ltd·Phase 1·NCT05611593·90 enrolled
A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes
Recruiting·SShenzhen People's Hospital·Phase 1/2·NCT07203599·59 enrolled
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
Recruiting·OOlix Pharmaceuticals, Inc.·Phase 1/2·NCT07327359·158 enrolled
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia
Recruiting·AAbsci Pty Ltd.·Phase 1/2·NCT07317544·227 enrolled
Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients
Recruiting·PPT. Prodia Stem Cell Indonesia·Phase 1/2·NCT07429253·40 enrolled
Umbilical Cord-derived Mesenchymal Stem Cell Exosomes on Hair Growth in Patients With Androgenetic Alopecia
Active, not recruiting·NNanfang Hospital, Southern Medical University·N/A·NCT06697080·50 enrolled
Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia
Not yet recruiting·SSheikh Zayed Federal Postgraduate Medical Institute·Phase 3·NCT07273799·200 enrolled
Various Procedural Treatment Options for Androgenetic Alopecia
Not yet recruiting·SSheikh Zayed Medical College·Phase 2·NCT06826001·190 enrolled
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
Not yet recruiting·SSuzhou Kintor Pharmaceutical Inc,·Phase 2/3·NCT06622824·756 enrolled
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
Not yet recruiting·IIndustrial Farmacéutica Cantabria, S.A.·Phase 3·NCT05888922·520 enrolled
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
Not yet recruiting·Chong Kun Dang Pharmaceutical logoChong Kun Dang Pharmaceutical·Phase 3·NCT06916793·288 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)